Opinion · 30 Dec 2025
Research articlePublished 2013
Abl Kinase Domain Mutations in Imatinib-treated Egyptian Patients with Chronic Myeloid Leukemia
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Background: Point mutations within ABL kinase domain (AKD) of the BCR-ABL gene are the most common cause of resistance to Imatinib Mesylate (IM) treated Chronic Myeloid Leukemia (CML) patients. Objectives: To assess the frequency, type and impact of AKD mutations on prognosis in a cohort of Egyptian CML patients. Patients and methods: Serial measurements of BCR-ABL transcripts level in 175 IM treated CML patients were performed using real time quantitative polymerase chain reaction (RQ-PCR). Mutation screening was performed by allele specific oligonucleotide polymerase chain reaction (ASO-PCR) in 72 patients including all 42 non-optimal responders; 28 resistant patients, 18 suboptimal responders in addition to 30 patients randomly selected with stable/ decreasing transcript level representing an optimal responder category. Results: AKD mutations were detected in 16/28 resistant patients (57%) at time of >2-fold rise in BCR-ABL transcript and in none of the 44 optimal or suboptimal responders (0%) with decreasing or stable transcript levels. From 16 positive patients, P-loop mutations were detected in 9 patients; Q252H in 3 patients (19%), Y253H in 2 patients (12%), Y253F in 2 patients (12%) and E255K in 2 patients (12%). T315I was detected in 1/16 (6%) patient. Regarding non P-loop mutation; V299L was detected in one patient (6%), M351T in 4 patients (25%), F359V in 2 patients (12%). One patient had both Y253H and E255K mutations. Ten/16 (62%) patients carrying mutations experienced disease progression versus 1/56 (2%) in non mutation group (p=0.001). Median progression free survival (PFS) and overall survival (OS) of the mutation group was 13.5 months and 37.5 months, respectively versus 42.6 months in non mutation group (p=0.001). The estimated PFS and OS at 49 months in patients with mutations were 37.5% and 56.3% respectively versus 98.2% in non mutation carriers (p2-folds in IM resistant patients may signal progression that implies testing for AKD mutations and early planning for second generation tyrosine kinase inhibitors (TKIs). P-loop mutations are significantly associated with advanced CML phases and poorer OS than non-P loop mutations. ASOPCR is a valuable tool for detection of mutations in countries where sequencing facilities are not available.
Subjects
HaematologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Leukemia.
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Leukemia
- SubjectHaematology
- BylineArticles whose byline prints “Yasser H Elnahass”
- BylineArticles whose byline prints “Hossam K Mahmoud”
- BylineArticles whose byline prints “Fahmy T Ali”
- BylineArticles whose byline prints “Mohamed R Mohamed”
- BylineArticles whose byline prints “Mahmoud M Said”
- BylineArticles whose byline prints “Mohamad Abdel Moaty Samra”
- BylineArticles whose byline prints “Mohamed AM Ali”
- BylineArticles whose byline prints “Amir Salem”
